Therapies targeting reactive oxygen species (ROS) and NAD+/PARP DNA repair have shown promise for SDHB tumours (Pang et al. 2018, Hadrava Vanova et al. 2021); and may become possible therapeutic options for SDHA tumours in the future. This evidence concerns the gene SDHA and neoplasm.